Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study evaluates the outcomes and critical factors influencing the success of tisagenlecleucel therapy for children and young adults with B-cell acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplant across Euro
This retrospective matched-pair study compares fludarabine combined with treosulfan or total body irradiation as conditioning regimens before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia, finding no significant
A large-scale retrospective study identifies Philadelphia chromosome positivity and high initial white blood cell counts as critical risk factors for central nervous system relapse in adult ALL patients following allogeneic HCT, suggesting
Campus ALL real-world data show that pre-transplant MRD negativity after the pediatric-inspired GIMEMA LAL1913 protocol predicts substantially better 3‑year OS and DFS after alloHSCT; MRD-positive patients and those in CR2 fare markedly wor
The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall s
In 164 adolescents and young adults with ALL transplanted in second remission, 3‑year overall survival was 53% and progression‑free survival 46%. MRD positivity and HCT‑Comorbidity Index >3 predicted worse outcomes; female‑to‑male donor
Elevated proinflammatory cytokines combined with low peripheral blood counts early after CD19 CAR-T cell infusion correlate with poor treatment response and severe toxicity in relapsed/refractory B-ALL, highlighting inflammation as a key mo